Pharmacogenomics of oxcarbazepine in the treatment of epilepsy
Related Experiment Video
Updated: Aug 1, 2025
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Yujie Yuan1, Shuang Zhang2, Yangyang Yuan3
1Judicial Appraisal Institution, Third Affiliated Hospital of Zhengzhou University, 7 Kangfu Qian Street, Zhengzhou, Henan, 450052, People's Republic of China.
Abstract:
Oxcarbazepine (OXC) is one of the preferred drugs for partial seizures and generalized tonic-clonic seizures. However, clinical studies have found that there are considerable differences among different populations in OXC therapeutic efficacy or safety that result from the function changes of metabolic enzymes, transporters and other receptors involved in pharmacokinetics and pharmacodynamics in vivo. The authors collected all the information on the clinically reported associations between variants of common genes (e.g., UGT1A9, HLA-B, ABCB1) and OXC. In conclusion, these associations based on variants are beneficial for adjusting the medication regimen, which could be useful for individualized treatment with OXC.
Insights
Genetic variations impact how well oxcarbazepine (OXC) works and its safety. Understanding these gene-drug associations helps personalize OXC treatment for better patient outcomes.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Neuroscience
Background:
- Oxcarbazepine (OXC) is a key antiepileptic drug for partial and generalized tonic-clonic seizures.
- Population-specific variability exists in OXC efficacy and safety due to genetic factors influencing drug metabolism and action.
- Genetic variations in enzymes, transporters, and receptors affect OXC pharmacokinetics and pharmacodynamics.
Purpose of the Study:
- To review and synthesize existing clinical data on gene variants associated with oxcarbazepine.
- To highlight the role of pharmacogenetics in understanding OXC response.
- To provide a basis for individualized oxcarbazepine therapy.
Main Methods:
- Systematic literature review of clinically reported gene-OXC associations.
- Analysis of common gene variants (e.g., UGT1A9, HLA-B, ABCB1) and their impact on OXC.
- Compilation of evidence linking genetic polymorphisms to OXC therapeutic outcomes.
Main Results:
- Identified significant associations between specific gene variants and OXC efficacy or safety profiles.
- Demonstrated that genetic variations in genes like UGT1A9, HLA-B, and ABCB1 influence OXC response.
- Collected comprehensive information on these clinically relevant gene-drug interactions.
Conclusions:
- Gene variants significantly influence oxcarbazepine pharmacokinetics and pharmacodynamics.
- Understanding these genetic associations is crucial for optimizing OXC treatment.
- Personalized medication regimens based on genetic profiles can improve OXC therapy.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:14Antiepileptic Drugs: Glutamate Antagonists